With the entire world’s focus – financial market or otherwise – turned almost exclusively to coronavirus, social distancing, and how long it is going to take for the world to return to any kind of normalcy in the foreseeable future, it isn’t all that surprising to see market commentary emphasizing health care. I’ve spent enough […]
Read MoreAs an investor that prefers to focus on value, my preference is to emphasize stocks that are currently trading at significant discounts to their basic valuation metrics. That usually means that most of my attention is directed on stocks that are also trading at or near to yearly or historical lows. That also means that […]
Read MoreFor the last few weeks, I believe that one of the biggest reasons investors, and the public at large have been so uncertain is simply because the scope of the spread of COVID-19 infection really is. Shelter-in-place orders in some cities and states followed stay-at-home and self-isolating policies that have taken place pretty much everywhere […]
Read MorePlus, the White House and congressional Democrats are beginning work on a fourth stimulus package, Simon Property Group has furloughed 30% of its workers amid the coronavirus pandemic, and Domino’s shares are down after the pizza chain said sales rose less investors had expected in the first quarter.
Read MoreTrade Setup Buy Target $60.15 Sell Target $70.57 Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor […]
Read MoreAt the beginning of my career in the financial industry, I was a licensed rep for one of the largest mutual fund and discount brokerage companies in North America. Looking over the mutual funds that we offered, and digging into their respective investment philosophies was something I found to be really fascinating. It wasn’t just […]
Read MorePlus, Pfizer announced it is initiating a program to screen antiviral drugs in its pipeline to identify possible treatments for the coronavirus, Target and Kohl’s reported earnings, and Thermo Fisher is buying Qiagen.
Read MoreTrade Setup Buy Target $7.25 Sell Target $7.85 Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells medicines for the treatment of cardio renal diseases in the United States and internationally. The company’s lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with […]
Read MorePlus, Bob Iger stepped down as Disney’s CEO, Ford’s COO says there’s a sense of urgency and crisis at the automaker, and Lowe’s reported mixed Q4 results.
Read MoreTrade Setup Buy Target $59.48 Sell Target $65.02 CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a revolutionary gene editing technology that allows for precise directed changes to genomic DNA. It […]
Read More